EPIX
ESSA Pharma Inc.
Set alert
0.20 0.00 0.00%
0.2012 Day range 0.2012
52-week range unavailable
- Open
- 0.2012
- Prev close
- 0.2012
- Mkt cap
- 72.35M
- Vol
- 5.95M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2012
- High
- 0.2012
- Forward P/E
- -3.26
- Beta
- 1.84
- Short ratio
- 0.32
- Inst. own
- 81.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 2.92
- 200-d avg
- 5.40
- 1y target
- 9.19
Key statistics
- Market cap
- 72.35M
- Enterprise value
- -57.59M
- Trailing P/E
- 0.00
- Forward P/E
- -3.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- EPS (TTM)
- -0.64
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.10M
- Total cash
- 130.69M
- Total debt
- 342.14K
- Return on equity
- -19.83%
- Shares outstanding
- 44.39M
- Short % of float
- 2.59%
- 50-day average
- 2.92
- 200-day average
- 5.40
Analyst view
Consensus: none
Price target (mean) 9.19 +4467.8% upside
Now 0.2012
- Target (low)
- 1.65
- Target (mean)
- 9.19
- Target (high)
- 30.99
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.255.
Financials — quick view
EPIX Revenue — quarterly 0
EPIX Net income — quarterly -4.00M
EPIX EPS — quarterly -0.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | -0.18 | — | — | — |
| Dec 17, 2024 | Sep 1, 2024 | -0.19 | -0.14 | +0.05 | +26.32% |
| Aug 5, 2024 | Jun 1, 2024 | -0.26 | -0.16 | +0.10 | +38.46% |
| May 14, 2024 | Mar 1, 2024 | -0.19 | -0.20 | -0.01 | -5.26% |
| Feb 13, 2024 | Dec 1, 2023 | -0.17 | -0.14 | +0.03 | +17.65% |
| Dec 12, 2023 | Sep 1, 2023 | -0.22 | -0.12 | +0.10 | +45.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2024 | Piper Sandler | down | Overweight | Neutral |
| Nov 4, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 1, 2024 | Jones Trading | down | Buy | Hold |
| May 16, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 13, 2023 | Oppenheimer | reit | Outperform | Outperform |
| Aug 9, 2023 | Oppenheimer | reit | Outperform | Outperform |
About ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- essapharma.com
News
- ESSA Announces Completion of Arrangement with XenoTherapeutics
- ESSA Securityholders Approve Acquisition by XenoTherapeutics
- ESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks Transcript
- ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
- Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on EPIX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 19.71% | 8,748,629 | 14.26M | Sep 29, 2024 |
| Bellevue Group AG | 17.75% | 7,879,583 | 12.84M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.66% | 4,288,167 | 6.99M | Sep 29, 2024 |
| Morgan Stanley | 9.42% | 4,181,342 | 6.82M | Sep 29, 2024 |
| RTW Investments LP | 7.35% | 3,261,496 | 5.32M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 6.18% | 2,742,936 | 4.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avantis U.S. Small Cap Equity ETF | 0.11% | 46,652 | 76.04K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 26,858 | 43.78K | Oct 30, 2024 |
| North Square Inv Tr-North Square Kennedy MicroCap Fund | 0.01% | 5,851 | 9.54K | Sep 29, 2024 |